Substance abuse is a significant social and economic burden upon Australian societies and on societies around the world. Treatment remains problematic due to the multi-layer nature of the disease, difficulties with treatment compliance and less than ideal treatment regimes. The present study aims to improve treatments for alcohol and drug abuse using pre-clinical models to identify and characterize a new brain system implicated in drug-seeking.
The Awakening:GABA-A Receptors As Targets For Improving Motor Function
Funder
National Health and Medical Research Council
Funding Amount
$735,498.00
Summary
Zolpidem (Stilnox) is a “sleeping pill” that is reported "awaken" people with severe motor, memory and speech disabilities that result from stroke or other brain injury. We have identified a novel target by which zolpidem can exert these effects. This project will characterise this target and assess drug effects in models of stroke.
?4-containing GABA-A Receptors As Targets For ?-hydroxybutyric Acid (GHB)
Funder
National Health and Medical Research Council
Funding Amount
$610,572.00
Summary
?-Hydroxybutyric acid (GHB) is an elusive substance. On one hand, it is a prescribed drug to treat narcolepsy, and ameliorate alcohol withdrawal. On the other hand, GHB is the club drug “Fantasy” or “Liquid Ecstasy”, taken by many Australians for its social, sexual and euphoric effects. This proposal will identify GHB targets and provide insight to its mechanism of action.
Targeting Small Airways To Overcome Resistance To Therapy In Asthma
Funder
National Health and Medical Research Council
Funding Amount
$531,045.00
Summary
There is a pressing need to overcome resistance to current therapies for severe asthma. Targetting inflammation-induced changes in small airway contraction offers an alternative strategy. We have identified a novel bronchodilator that relaxes maximally contracted mouse small airways when current treatment is ineffective. We will demonstrate its efficacy in animal models mimicking key features of human asthma, and define new ways to improve outcomes in poorly-controlled asthma.